Secondary mutations at I1171 in the ALK gene confer resistance to both crizotinib and alectinib

Gouji Toyokawa, Fumihiko Hirai, Eiko Inamasu, Tsukihisa Yoshida, Kaname Nosaki, Tomoyoshi Takenaka, Masafumi Yamaguchi, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose

Research output: Contribution to journalArticle

46 Citations (Scopus)
Original languageEnglish
Pages (from-to)e86-e87
JournalJournal of Thoracic Oncology
Volume9
Issue number12
DOIs
Publication statusPublished - Jan 1 2014

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Toyokawa, G., Hirai, F., Inamasu, E., Yoshida, T., Nosaki, K., Takenaka, T., Yamaguchi, M., Seto, T., Takenoyama, M., & Ichinose, Y. (2014). Secondary mutations at I1171 in the ALK gene confer resistance to both crizotinib and alectinib. Journal of Thoracic Oncology, 9(12), e86-e87. https://doi.org/10.1097/JTO.0000000000000358